Avantor Faces Securities Fraud Class Action; Investors Urged to Note Deadline
Written by Emily J. Thompson, Senior Investment Analyst
Source: Globenewswire
Updated: 52 minutes ago0mins
- Class Action Reminder: Bernstein Liebhard LLP alerts Avantor investors about a securities fraud class action lawsuit filed in the U.S. District Court for the Eastern District of Pennsylvania, alleging misrepresentations regarding the company's competitive positioning for stock purchases made between March 5, 2024, and October 28, 2025.
- Investor Losses: Investors who purchased Avantor shares during this period and incurred losses must file to become lead plaintiffs by December 29, 2025, enabling them to represent other shareholders in the litigation.
- Fee Structure: All representation is on a contingency fee basis, meaning shareholders incur no fees or expenses, which reduces the financial burden on investors and encourages broader participation from affected parties.
- Law Firm Background: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has been recognized multiple times in The National Law Journal’s “Plaintiffs’ Hot List,” showcasing its strong track record in protecting investor rights.
AVTR.N
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on AVTR
Wall Street analysts forecast AVTR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVTR is 13.86 USD with a low forecast of 12.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
4 Buy
6 Hold
0 Sell
Moderate Buy
Current: 10.930
Low
12.00
Averages
13.86
High
17.00
Current: 10.930
Low
12.00
Averages
13.86
High
17.00
Raymond James
Outperform -> Market Perform
downgrade
2025-11-04
Reason
Raymond James
Price Target
2025-11-04
downgrade
Outperform -> Market Perform
Reason
Raymond James downgraded Avantor to Market Perform from Outperform without a price target. The company reported another "frustrating quarter" with a miss on sales, the analyst tells investors in a research note. The firm cites Avantor's reduced guidance and execution risks for the downgrade. Raymond James sees a lack of visibility to continue recommending the shares.
Barclays
Luke Sergott
Overweight -> Equal Weight
downgrade
$15 -> $12
2025-10-30
Reason
Barclays
Luke Sergott
Price Target
$15 -> $12
2025-10-30
downgrade
Overweight -> Equal Weight
Reason
As previously reported, Barclays analyst Luke Sergott downgraded Avantor to Equal Weight from Overweight with a price target of $12, down from $15. The company is not committing to earnings and sales growth next year given the early stages of its strategic review process, the analyst tells investors in a research note. Barclays awaits further details on Avantor's "revival" plan before again recommending the shares.
JPMorgan
Overweight -> Neutral
downgrade
$14 -> $12
2025-10-30
Reason
JPMorgan
Price Target
$14 -> $12
2025-10-30
downgrade
Overweight -> Neutral
Reason
JPMorgan downgraded Avantor to Neutral from Overweight with a price target of $12, down from $14. The company reported another "weak" quarter and its guide-down indicates limited turnaround visibility, the analyst tells investors in a research note. The firm finds it unclear when some of Avantor's "transitory and seemingly idiosyncratic" issues will subside, such as the operational headwinds impacting process chemicals.
Barclays
Luke Sergott
Overweight -> Equal Weight
downgrade
$15 -> $12
2025-10-30
Reason
Barclays
Luke Sergott
Price Target
$15 -> $12
2025-10-30
downgrade
Overweight -> Equal Weight
Reason
Barclays analyst Luke Sergott downgraded Avantor to Equal Weight from Overweight with a price target of $12, down from $15.
See All Ratings
About AVTR
Avantor, Inc. is a life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. The Company’s segments include Laboratory Solutions and Bioscience Production. Within its segments, it sells materials and consumables, equipment and instrumentation and services and specialty procurement to customers in the biopharma and healthcare, education and government and advanced technologies and applied materials industries. Materials and consumables include ultra-high purity chemicals and reagents, lab products and supplies, highly specialized formulated silicone materials, customized excipients, and others. Equipment and instrumentation include filtration systems, virus inactivation systems, incubators, analytical instruments, and others. Services and specialty procurement include onsite lab and production, equipment, procurement and sourcing and biopharmaceutical material scale-up and development services.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
What are the key allegations against Avantor in the class action lawsuits?
Why is Avantor's competitive positioning considered weaker than previously disclosed?
How might Avantor's stock price react if the lawsuits result in settlements?
What could happen to Avantor's market share if competition continues to increase?